- Diagnostic Différentiel
Drug Information for ONGLYZA (saxagliptin) tablets Initial U.S. Approval: 2009 (E.R. Squibb & Sons, L.L.C.): 10 OVERDOSAGE
- 4 CONTRAINDICATIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 14 CLINICAL STUDIES
- 17 PATIENT COUNSELING INFORMATION
- Liens externes liés à ONGLYZA (saxagliptin) tablets Initial U.S. Approval: 2009 (E.R. Squibb & Sons, L.L.C.)
In a controlled clinical trial, once-daily, orally-administered ONGLYZA in healthy subjects at doses up to 400 mg daily for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on QTc interval or heart rate.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status. Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours).
- Drug Information Provided by National Library of Medicine (NLM).